Eden Biologics, Inc. Announces the Completion of the Sale of CDMO Business Assets
Bora is paying $50 million to $100 million to get its hands on the local contract manufacturing assets of Eden Biologics, formerly known as JHL Biotech, as it works to grow its biologics CDMO.
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan`s CDMO sector as it continues to expand into the global CDMO market
Biotech co-founders admit to stealing secrets from Genentech
Two co-founders of JHL Biotech were charged on Wednesday with stealing trade secrets from Genentech that helped their firm speed development of generic versions of Genentech biologic drugs, the U.S. Justice Department said in a statement.
On September 9, 2020, Genentech, Inc. and JHL Biotech, Inc. filed a stipulation for entry of a proposed consent judgment and permanent injunction as to JHL Biotech, Inc. That proposed consent judgment and permanent injunction is the result of the parties’ June 18, 2020 settlement agreement, in which JHL represented that it had ceased and abandoned development and/or clinical trials of JHL 1101 (rituximab), JHL 1921 and JHL 1922 (dornase alfa), JHL 1149 (bevacizumab), and JHL 1188 (trastuzumab). Furthermore, JHL represented in the settlement agreement that it had ceased the use and disclosure of any Genentech confidential information, that it would provide employee training regarding the acquisition and use of confidential information, and that any employee or consultant hired from Genentech, Roche Holdings Ltd, or affiliates would review the Proprietary Information Agreement with Genentech/Roche.
JHL Biotech, Inc. has announced a signing of a Master Service Agreement (“MSA”) with Adimmune Corporation, a Taiwanese vaccine company, to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.